Fibroblast Growth Factors，2nd edition
定 價：420 元
- 作者：Xiaokun，Li 著
- 出版時間：2019/10/1
- ISBN：9787040528695
- 出 版 社：高等教育出版社
- 中圖法分類：R329.2
- 頁碼：1024
- 紙張：膠版紙
- 版次：2
- 開本：16開
Fibroblast growth factors （FGFs） are secreted protein ligands that act in a paracrine or endocrine fashion to carr3r out their pleiotropic functions in development， tissue homeostasis and metabolism. Especially in recent years， more and more attention has been paid to this super family. tn the past 30 years， Prof. Xiaokun Li's research team has been focused on the field of basic mechanism and bioengineering of FGFs in China. This book is the second version which collected research results of Li's group from 2013 to 2018. All these 9 chapters spans reviews of FGFs， injury repair and regeneration， metabolism， structure and modification， signalling pathway and pharmacology， pharmaceutics and new materials， bioreactor and engineering as well as FGF/FGFR inhibitors and others. This work should be a helper primer to scientists and particularly young students entering the FGFs field with their eye toward basic research and application.
Professor Xiaokun Li invited me to write a preface for his new book titled Fibroblast Growth Factors （the second edition 2，013-2018）. It reminded me of what happened more than 27 years ago. At that time， Xiaokun Li and were all young scientists. We were working together on rbFGF （recombinant basic Fibroblast Growth Factor）， a new wound repair biopharmaceutic. That was the beginning of the age of biomediane development for trauma in China. We have encountered many difficulties and frustrations， but we succeeded in this field. The rbFGF became one of the earliest approved new drugs for wound repair in China.
Fibroblast growth factors （FGFs） are one kind of growth factors. they act in a paracrine or endocrine fashion to carry out their functions in development， tissue homeostasis and metabolism. The bFGF is the second member in the FGF family of 23 members. In China， EGF （Epidermal Growth Factor） and bFGF have been approved for use in acute skin wounds and chronic ulcers. Up to now， the data show that topical application of a single growth factors effective in accelerating acute or chronic wound healing. The average wound healing time in acute skin wounds can be shortened by 2 to 4 days when locally treated with growth factors. Also， those wounds such as \"hard-to-heal\" diabetic foot ulcers or pressure sores show significant improvement in the healing rate and the time compared with cohort controls. Importantly， besides its treatment efficacy， clinical evaluation and follow up on the healing of chronic cutaneous wounds confirmed its safety in that no adverse side-effects related to bFGF were observed. The results further established both the effectiveness and safety of using rbFGF to accelerate healing in chronic wounds.
Xiaokun Li，M.D.. Ph.D.， is an honored scientist in the field of medical sciences. specifically with respect to Microbiology， Moleccular biology， Pharmacology，Biomedical engineering of Fibroblast Growth Factors （FGFs）.He hold his M.D. from Bethune Medical University， Changchun （1987）， and got a Ph.D in Microbiology from Sun Yat-sen Medical University， Guangzhou（1996）. Since 1992. he has held vice director position in Bioengineering Insitute at Jinan University， where he started working on the FGFs research. Dr. Li's interests are focused on the field of basic mechanism and bioengineering of FGFs. In the almost 30 years， his three A grade FCF new drugs were approved and commercialized， aswell as several new drugs such as FGF21， FGF10 are going on clinical trial. Moreover， he published about 196 papers on FGFs in such as Nature， Cell Metabolism，Molecular Cell and so on. In recent years， he proposed the new \"FGF axes\" theory according to his research results and important scientific discovery.
At present， he serves as the president of Wenzhou Medical University and the chairman of International Chinese FGF Association.
The FGF Metabolic Axis
Chapter 1 Growth Factors Reviews
Fibroblast growth factors， old kids on the new block
Pharmacological application of growth factors： basic and clinical
Cytokines and diabetes research
Small molecule inhibition of fibroblast growth factor receptors in cancer
Research advances in tissue engineering materials for sustained release of growth factors
Minireview： roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases
Physiological and pharmacological roles of FGF21 in cardiovascular diseases
Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury
Delivery of growth factor-based therapeutics in vascular diseases： challenges and strategies
Fibroblast growth factor 10 in pancreas development and pancreatic cancer
Chapter 2 Injury Repair and Regeneration
TAT-mediated acidic fibroblast growth factor delivery to the dermis improves wound healing of deep skin tissue in rat
Regulation of autophagy and ubiquitinated protein accumulation by bFGF promotes functional recovery and neural protectzion in a rat model of spinal cord injury
The anti-scar effects of basic fibroblast growth factor on the wound repair in vitro and in vivo
Exogenous basic fibroblast growth factor inhibits ER Stress-induced apoptosis and improves recovery from spinal cord injury
FGF10 protects against renalischemia/reperfusion injury by regulating autophagy and infiammatory signaling
Reduction of cellular stress is essential for Fibroblast growth factor 1 treatment for diabetic nephropathy
Chapter 3 Endocrinology and Metabolism
Fibroblast growth factor 21 （FGF21） therapy attenuates left ventricular dysfunction and metabolic disturbance by improving FGF21 sensitivity， cardiac mitochondrial redox homoeostasis and structural changes in pre-diabeticrats
NMR-based metabolomics reveal a recovery from metabolic changes in the striatum of 6-OHDA-induced rats treated with basic fibroblast growth factor
FGF21 mediates alcohol-induced adipose tissuelipolysis by activation of systemic release of catecholamine inmice
Fibroblast growth factor 21 deletion aggravates diabetes-induced pathogenic changes in the aorta in type 1 diabetic mice
Additive protection by LDR and FGF21 treatment against diabetic nephropathy in type 2 diabetes model
FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation
Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectininmice
Attenuation of hyperlipidemia and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration offibroblast growth factor-21 is associated with suppression of renal infiammation
The prevention of diabetic cardiomyopathy by non-mitogenic acidic fibroblast growth factor is probably mediated by the suppression of oxidative stress and damage
Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling-dependent manner
……
Chapter 4 Structure and Modification
Chapter 5 Signaling Pathway and Pharmacology
Chapter 6 Pharmaceutics and New Material
Chapter 7 Bioreactor and Engineering
Chapter 8 FGFR and Inhibitors
Chapter 9 Others
書單推薦
